Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type

The frequency and significance of p53 alterations in cutaneous melanoma have not been completely clarified. In the present study, 31 primary melanomas of the nodular type and 15 metastases occurring between 1981 and 1983 were studied with respect to mutations in exons 7 and 8, as well as to p53 protein immunostaining using different antibodies. Altogether 13% of the primary tumors showed strong p53 staining using the DO‐7 antibody. Different results were obtained with other antibodies. Seven mutations were found in primary and metastatic tumors; all of these were single base changes, most of which occurred in the core domain of the p53 protein responsible for sequence‐specific DNA binding (residues 102–293). The mutations were not significantly associated with p53 staining results, and p53 alterations (mutations or marked immunopositivity) had no prognostic value. Our results indicate that point mutations in exons 7 and 8 are more frequent than previously reported in primary melanomas, and such changes may be important for the development of certain melanoma subgroups. Int. J. Cancer (Pred. Oncol.) 79:91–95, 1998. © 1998 Wiley‐Liss, Inc.

[1]  L. Akslen,et al.  Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma , 1997, International journal of cancer.

[2]  A. Hartmann,et al.  Overexpression and mutations of p53 in metastatic malignant melanomas , 1996, International journal of cancer.

[3]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[4]  D. English,et al.  Prognostic significance of p53 over‐expression in thin melanomas , 1995, Melanoma research.

[5]  D. Levin,et al.  Detection of p53 mutations in benign and dysplastic nevi. , 1995, Cancer research.

[6]  H. Pilch,et al.  Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications , 1995, The British journal of dermatology.

[7]  V. A. Flørenes,et al.  Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome , 1995, Melanoma research.

[8]  E. Brambilla,et al.  p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[10]  P. Kleihues,et al.  Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.

[11]  J. Nesland,et al.  TP53 allele loss, mutations and expression in malignant melanoma. , 1994, British Journal of Cancer.

[12]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[13]  A. Levine,et al.  The mdm-2 gene is induced in response to UV light in a p53-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Sober,et al.  Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma , 1993, International journal of cancer.

[15]  E. Cesarman,et al.  High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. , 1993, The American journal of pathology.

[16]  W. Cavenee,et al.  Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.

[17]  M. Barbareschi,et al.  p53 Protein expression in nevi and melanomas. , 1993, Archives of dermatology.

[18]  D. Barnes,et al.  p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.

[19]  N. Lassam,et al.  Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.

[20]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[21]  T. Sano,et al.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. , 1992, Cancer research.

[22]  L. Akslen,et al.  Expression of p53 protein in cutaneous melanoma , 1992, International journal of cancer.

[23]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[24]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Harris,et al.  Expression of mutant p53 in melanoma. , 1991, Cancer research.

[26]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[27]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.